



CLIA/GLP Validated MGMT Methylation Controls

MGMT METHYLATION

Glioblastoma is the most common form of primary brain cancer in adults, with a median survival rate of 12-15 months. Although nearly all glioblastomas recur, initial treatments may keep the tumor controlled for months or even years. MGMT promoter methylation has been shown to be associated with improved outcomes in glioblastoma patients, especially after treatment with alkylating chemotherapy. This is due to the role of MGMT as a DNA repair enzyme. Inactivation of MGMT expression by methylation results in a decrease in DNA repair capabilities, leading to greater sensitivity to alkylating agents, such as temozolomide. Therefore, our MGMT methylation tests can help guide clinicians with treatment decisions.



EpigenDx offers 4 validated MGMT methylation tests covering a total of 25 CpG sites in the Promoter, Exon 1, and Intron 1 regions of the MGMT gene:

Information: Human MGMT Methylation Assays

Platform:	Bisulfite pyrosequencing
Species:	Human (Homo sapiens)
Overall Stats:	25 CpG sites in the Promoter, Exon 1, and Intron 1 regions
ASY514A	6 CpG sites in the Promoter region
ASY470-FS1	7 CpG sites in the Exon 1 region
ASY470-FS2	8 CpG sites in the Exon 1 & Intron 1 regions
ASY1518	4 CpG sites in the Intron 1 region



MGMT Methylation Analysis Service

- Send your samples to EpigenDx's CLIA service laboratory
- Ability to accept all types of samples (FFPE, serum, plasma, whole blood, extracted DNA, bisulfite-converted DNA)
- Pyrosequencing platform with rapid turnaround times
- Full results report delivered in individual patient or batch format
- QA audit and QA report available as needed for clinical trial samples

MGMT Methylation Analysis Service

- Primers compatible with Pyrosequencing and Real-Time PCR based HRM technologies
- Primers good for 300 reactions
- Access to our knowledgeable and experienced customer service